These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 26551485)

  • 1. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
    Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
    J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
    Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
    Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
    Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
    Front Immunol; 2018; 9():2467. PubMed ID: 30410490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Proteasome and Myeloma-Associated Bone Disease.
    Accardi F; Toscani D; Costa F; Aversa F; Giuliani N
    Calcif Tissue Int; 2018 Feb; 102(2):210-226. PubMed ID: 29080972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.
    Giuliani N; Ferretti M; Bolzoni M; Storti P; Lazzaretti M; Dalla Palma B; Bonomini S; Martella E; Agnelli L; Neri A; Ceccarelli F; Palumbo C
    Leukemia; 2012 Jun; 26(6):1391-401. PubMed ID: 22289923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
    Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
    Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid Hormone (PTH) Induces Autophagy to Protect Osteocyte Cell Survival from Dexamethasone Damage.
    Zhu L; Chen J; Zhang J; Guo C; Fan W; Wang YM; Yan Z
    Med Sci Monit; 2017 Aug; 23():4034-4040. PubMed ID: 28824162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
    Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
    Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
    Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
    Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
    de Oliveira MB; Sanson LFG; Eugenio AIP; Barbosa-Dantas RSS; Colleoni GWB
    Curr Mol Med; 2019; 19(2):112-119. PubMed ID: 30834832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of estrogen status in osteocyte autophagy and its relation to osteocyte viability in alveolar process of ovariectomized rats.
    Florencio-Silva R; Sasso GRS; Sasso-Cerri E; Simões MJ; Cerri PS
    Biomed Pharmacother; 2018 Feb; 98():406-415. PubMed ID: 29276969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma.
    Archer CR; Koomoa DL; Mitsunaga EM; Clerc J; Shimizu M; Kaiser M; Schellenberg B; Dudler R; Bachmann AS
    Biochem Pharmacol; 2010 Jul; 80(2):170-8. PubMed ID: 20362557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting autophagy in multiple myeloma.
    Yun Z; Zhichao J; Hao Y; Ou J; Ran Y; Wen D; Qun S
    Leuk Res; 2017 Aug; 59():97-104. PubMed ID: 28599191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
    Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
    Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy.
    Lohberger B; Steinecker-Frohnwieser B; Stuendl N; Kaltenegger H; Leithner A; Rinner B
    PLoS One; 2016; 11(12):e0168193. PubMed ID: 27978543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib induces apoptosis and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro.
    Lou Z; Ren T; Peng X; Sun Y; Jiao G; Lu Q; Zhang S; Lu X; Guo W
    J Int Med Res; 2013 Oct; 41(5):1505-19. PubMed ID: 23975859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors.
    Chao A; Wang TH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):3-8. PubMed ID: 26927239
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Wu H; Liu C; Yang Q; Xin C; Du J; Sun F; Zhou L
    Autophagy; 2020 Apr; 16(4):683-697. PubMed ID: 31242129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.
    Jagannathan S; Abdel-Malek MA; Malek E; Vad N; Latif T; Anderson KC; Driscoll JJ
    Leukemia; 2015 Nov; 29(11):2184-91. PubMed ID: 26108695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.